Technical Analysis for ADVM - Adverum Biotechnologies, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Crossed Above 20 DMA | Bullish | -0.50% | |
| NR7 | Range Contraction | -0.50% | |
| Gapped Up | Strength | -0.50% | |
| Up 3 Days in a Row | Strength | -0.50% | |
| Up 4 Days in a Row | Strength | -0.50% | |
| 50 DMA Support | Bullish | 2.33% |
| Alert | Time |
|---|---|
| Possible NR7 | about 5 hours ago |
| 20 DMA Support | about 10 hours ago |
| Rose Above Previous Day's High | about 10 hours ago |
| Up 2% | about 10 hours ago |
| Up 1% | about 10 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/07/2024
Adverum Biotechnologies, Inc. Description
Adverum Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Gene Therapy Macular Degeneration Genetic Diseases Retina Wet Age Related Macular Degeneration Rare Genetic Disease Gene Therapy Products Regeneron Adverum Biotechnologies Gene Therapy Of The Human Retina
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 29.7 |
| 52 Week Low | 6.38 |
| Average Volume | 182,755 |
| 200-Day Moving Average | 10.28 |
| 50-Day Moving Average | 7.40 |
| 20-Day Moving Average | 7.89 |
| 10-Day Moving Average | 7.73 |
| Average True Range | 0.40 |
| RSI (14) | 54.55 |
| ADX | 17.91 |
| +DI | 22.47 |
| -DI | 17.44 |
| Chandelier Exit (Long, 3 ATRs) | 7.37 |
| Chandelier Exit (Short, 3 ATRs) | 8.36 |
| Upper Bollinger Bands | 8.47 |
| Lower Bollinger Band | 7.31 |
| Percent B (%b) | 0.51 |
| BandWidth | 14.62 |
| MACD Line | 0.08 |
| MACD Signal Line | 0.12 |
| MACD Histogram | -0.04 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.28 | ||||
| Resistance 3 (R3) | 8.31 | 8.21 | 8.21 | ||
| Resistance 2 (R2) | 8.21 | 8.12 | 8.20 | 8.19 | |
| Resistance 1 (R1) | 8.06 | 8.06 | 8.01 | 8.03 | 8.17 |
| Pivot Point | 7.96 | 7.96 | 7.94 | 7.95 | 7.96 |
| Support 1 (S1) | 7.81 | 7.87 | 7.76 | 7.78 | 7.63 |
| Support 2 (S2) | 7.71 | 7.81 | 7.70 | 7.61 | |
| Support 3 (S3) | 7.56 | 7.71 | 7.59 | ||
| Support 4 (S4) | 7.53 |
